UNSPSC 51310000: Antihistamines or H1 blockers

This classification denotes drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists, and which thereby act in the bronchi, capillaries, and other smooth muscles to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence.

UNSPSC 51310000 Antihistamines or H1 blockers is a Family code that in recent state and local procurement activity encompasses a broader range of pharmaceutical and over-the-counter products than the code name suggests. State and local buyers under this code are purchasing generic multi-source pharmaceuticals, naloxone, drug deactivation systems, and other OTC health products through competitive bidding and cooperative purchasing arrangements. The issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Seminole County, Florida and the Texas Health and Human Services Commission represent recent activity, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, operates a standing cooperative vehicle serving multiple states including Oregon.

Recent opportunities reflect two procurement models: direct acquisitions by individual counties and state agencies, and cooperative purchasing frameworks that establish multiple-award schedules for broader distribution. Seminole County issued IFB 60459723LAS on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling early-stage market research before formal solicitation. MMCAP issued an RFP for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026, due March 26, 2026) establishing contracts effective July 1, 2026, requiring vendors to work through three authorized wholesalers and meet FDA compliance, cGMP certification, and Drug Supply Chain Security Act requirements. Recent activity concentrates in Florida, Texas, and the upper Midwest, with broader geographic reach through cooperative purchasing vehicles.